Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors

Area of Science:

• Oncology
• Pharmacology

Background:

• Fibroblast growth factor receptor (FGFR) signaling pathway is a target for novel cancer drugs.
• Approved FGFR inhibitors like lenvatinib and dovitinib are used in clinical practice for cancer therapy.
• Many FGFR inhibitors are still in preclinical or clinical research stages.

Purpose of the Study:

• To review the pharmacological characteristics of FGFR inhibitors for combination therapy.
• To present preclinical data supporting the use of FGFR inhibitors in combination regimens.
• To discuss clinical implications and challenges of FGFR inhibitor combination strategies.

Main Methods:

• Literature review of preclinical and clinical studies on FGFR inhibitors.
• Analysis of pharmacological properties of various FGFR inhibitors.
• Evaluation of data supporting combination therapies involving FGFR inhibitors.

Main Results:

• FGFR inhibitors, including tyrosine kinase inhibitors, selective inhibitors, and monoclonal antibodies, are being developed.
• Combination of FGFR inhibitors with other therapeutic agents may overcome resistance and enhance sensitivity.
• Approved non-specific FGFR inhibitors are available, but most novel agents are in research phases.

Conclusions:

• Combination regimens involving FGFR inhibitors hold potential for enhanced cancer treatment.
• Further research is needed to address clinical implications and challenges for combination therapies.
• Optimizing FGFR inhibitor combinations could improve outcomes for diverse solid tumors.